Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The Department of War, through the Defense Health Agency, is soliciting quotations to support the establishment and maintenance of the Uniform Formulary for the Military Health System, as mandated by federal law and regulation. The process involves evaluating newly approved pharmaceutical agents for clinical and cost effectiveness to determine their inclusion in the Uniform Formulary tiers—generic, formulary, Basic Core Formulary, Extended Core Formulary, or non-formulary—with associated cost-sharing implications. The evaluation will focus on nine specific drugs scheduled for review in August 2026, including atoncy, baxfendy, duloxetine, filkri, hepcludex, lynavoy, veppanu, xocova, and xtoro. Filkri and lynavoy are only eligible for the Additional Discount Program due to non-TAA compliance. The resulting agreements, Uniform Formulary Blanket Purchase Agreements and Uniform Formulary Additional Discount Program Agreements, will be awarded based on the P&T Committee’s recommendations and vendor responses. The solicitation, identified as HT9402-26-Q-9304, requires industry responses by July 27, 2026, following a mandatory pre-quotation teleconference on July 15, 2026. All clinical and technical responses must be submitted to designated point of contacts via email by the specified deadline. The contracting office is located in Aurora, Colorado, with performance expected in San Antonio, Texas. The National Institute of Standards and Technology code for this action is 325412, and all submissions must comply with the detailed instructions contained in the RFQ document. Primary and secondary points of contact are provided for inquiries and submission guidance, ensuring full alignment with federal procurement and pharmacy benefits requirements.
General Info
Agency
NAICS
Place of Performance
TX, 78230, USASet-Aside
Timeline
Response Deadline
Organization & Contact Information
Full Description
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: The following August 2026 newly approved drugs will be reviewed:
a. Atoncy – ADHD Agents – Subclass: Non-stimulants
b. Baxfendy – Diuretics – Subclass: Mineralocorticoid Receptor Antagonists
c. Duloxetine - Antidepressants And Non-opioid Pain Syndrome Agents – Subclass: SNRI
d. Filkri – White Blood Cell Stimulants – Subclass: Filgrastims (Only ADP eligible due to non-TAA compliance)
e. Hepcludex – Hepatitis D Agent – Subclass: NA
f. Lynavoy – Gastrointestinal-2 Agents – Subclass: NA
g. Veppanu - Breast Cancer Agents – Subclass: Estrogen Receptor Antagonist
h. Xocova – Antivirals – Subclass: FDA Approved COVID Therapeutics
i. Xtoro - Antibiotics – Subclass: Quinolones
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9304.
Pre-quotation teleconference is on July 15, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POCs in Part 2.3.1., no later than the date stated in Part 2.3.2.
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Defense → Defense Health Agency
Same awarding agency